Does Insurance Cover Ketamine Therapy?

If you are looking into ketamine therapy for depression, one of the first things you will want to know is whether your insurance will help pay for it. The answer is not a simple yes or no — it depends heavily on which form of ketamine you are considering, what your diagnosis is, and what your specific plan covers.

Here is the practical picture for patients in the United States in 2026.

The short answer

Insurance is much more likely to cover Spravato than IV ketamine. Spravato is the brand name for esketamine nasal spray, and it has FDA-approved uses for treatment-resistant depression in adults and for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. Because it has FDA approval for those specific conditions, many commercial insurance plans, Medicare, and some Medicaid plans will cover it — usually after prior authorization.

IV ketamine, IM ketamine, oral ketamine, and at-home ketamine programs used for depression are a different story. The FDA has not approved ketamine itself for any psychiatric disorder. Insurers routinely classify these treatments as off-label, investigational, or unproven, which means they are usually self-pay.

That distinction — FDA-approved Spravato versus off-label IV ketamine — is the single most important thing to understand about ketamine insurance coverage.

What insurers are more likely to cover

Spravato for qualifying diagnoses. When a patient meets the plan's medical-necessity criteria, Spravato is the form of ketamine therapy most likely to receive insurance coverage. Major insurers including Aetna, Cigna, UnitedHealthcare, and Premera all publish coverage policies for Spravato. The typical requirements include a qualifying diagnosis (treatment-resistant depression or MDD with acute suicidal ideation), documented failure of at least two prior antidepressants, and prior authorization before treatment begins.

Coverage does not mean free. Even with insurance approval, patients are usually responsible for copays, coinsurance, or deductible costs. The drug itself, the office visit, clinician supervision, and the mandatory two-hour observation period may each be billed separately — and not all components are always covered the same way. The manufacturer offers a savings program (SPRAVATO withMe) that can reduce out-of-pocket costs for eligible commercially insured patients, sometimes to as little as $0 to $62 per session. That program does not apply to government-funded insurance like Medicare or Medicaid.

Important: a published coverage policy from a major insurer does not guarantee that every employer plan or member plan under that insurer covers Spravato the same way. Plans vary, and verification matters.

What insurers often do not cover

IV ketamine for depression is the most common treatment patients ask about, and it is the one most likely to be self-pay. Aetna explicitly classifies ketamine-assisted therapy for depression as experimental, investigational, or unproven. Premera states that esketamine in formulations other than Spravato nasal spray — including intravenous, intramuscular, subcutaneous, or oral forms — is investigational for treatment of any symptom or condition.

The same applies to IM injections, oral ketamine, sublingual troches, and at-home ketamine programs when used for psychiatric conditions. These are not FDA-approved for depression, and insurers generally will not cover them.

Massachusetts General Hospital puts it plainly on its clinic page: IV ketamine is currently not covered by most insurances and is generally out-of-pocket, while its esketamine (Spravato) service is covered by most insurances after prior authorization.

To be fair, "usually self-pay" is not the same as "never covered." Rare exceptions exist — some plans, some diagnoses, some circumstances may lead to partial coverage. But patients should plan on paying out of pocket for IV ketamine and treat any insurance help as a bonus rather than an expectation.

If you are paying out of pocket, our article on how much ketamine therapy costs breaks down typical pricing by treatment type.

Why the coverage gap exists

The difference comes down to FDA approval.

Spravato went through the FDA approval process for specific depression-related indications. That gives insurers a regulatory basis to cover it. Ketamine itself, despite decades of use as an anesthetic and growing evidence for its psychiatric applications, has never gone through the FDA approval process for depression or other mental health conditions. No pharmaceutical company has sponsored it through that process, largely because ketamine is a generic drug with no patent protection — there is little financial incentive to fund the expensive clinical trials required.

The result is a structural gap: the treatment with the most clinical experience (IV ketamine) is the hardest to get covered, while the branded, FDA-approved version (Spravato) is more accessible through insurance. That frustrates a lot of patients and providers, but it is the current reality.

Medicare

Medicare may cover Spravato in some circumstances, but the details matter.

Medicare Part B generally covers outpatient drugs that are administered by a provider in a doctor's office or hospital outpatient setting — as opposed to drugs patients take at home on their own. Spravato fits this model because it must be given in a REMS-certified healthcare setting under direct observation, with at least two hours of post-dose monitoring. Medicare billing guidance includes specific codes for Spravato administration visits.

That said, coverage is not automatic for every beneficiary. Medical necessity, diagnosis, the specific Medicare plan (traditional Medicare vs. Medicare Advantage), and local contractor rules all play a role. Patients on Medicare should verify coverage with their plan before starting treatment.

For IV ketamine, Medicare coverage is unlikely when the treatment is being used for depression or other psychiatric conditions, for the same off-label reasons that apply to commercial insurance.

Medicaid

Medicaid is even more variable because each state runs its own program, and many states contract with managed-care organizations that set their own formulary and prior-authorization rules.

Some state Medicaid programs do cover Spravato. Florida Medicaid, for example, publishes prior-authorization criteria requiring an adult patient, a qualifying diagnosis, documented prior antidepressant trials, concurrent use of an oral antidepressant, and monitored administration. UnitedHealthcare's Community Plan in Arizona publishes its own Medicaid criteria with different requirements and approval periods.

That kind of state-by-state and plan-by-plan variation is exactly why patients cannot assume Medicaid will or will not cover ketamine therapy without checking their specific plan. If you are on Medicaid, call the number on your card and ask specifically about Spravato coverage for your diagnosis.

How to verify your benefits before booking

Before scheduling treatment, take these steps:

Call your insurer directly. Ask whether Spravato is covered for your diagnosis, whether prior authorization is required, whether the clinic you are considering is in-network, and what your expected out-of-pocket cost would be (copay, coinsurance, deductible). Ask whether the observation period is covered separately from the drug.

Ask about benefit type. Spravato may be covered under the medical benefit, the pharmacy benefit, or both — and the cost-sharing rules can be different depending on which one applies. Ask your insurer which benefit applies to your plan.

Ask the clinic. Good clinics will help with this process. Massachusetts General Hospital says it obtains prior authorization for patients who meet esketamine criteria. Johns Hopkins says it reviews records and seeks insurance approval for appropriate patients. When comparing clinics, look for ones that actively help with benefits verification and prior authorization — it can save you significant time and frustration.

Get it in writing. If your insurer says something is covered over the phone, ask for written confirmation or a reference number. Verbal approvals are not always honored when the bill arrives.

What can cause a denial

Even for Spravato, coverage can be denied. Common reasons include:

• No qualifying diagnosis on file
• Not enough documented prior antidepressant failures
• Clinic not REMS-certified or not meeting monitoring requirements
• Out-of-network provider
• Plan-specific exclusions for the treatment or diagnosis
• Missing or incomplete prior authorization

If your claim is denied, ask for the reason in writing. Then ask whether additional documentation — more detailed medical records, a letter from your prescriber, or a peer-to-peer review between your doctor and the insurer's medical reviewer — could change the outcome. You have the right to appeal, and Medicare beneficiaries have a formal five-level appeal process for drug coverage decisions.

Questions to ask a ketamine clinic about insurance

Before booking your first appointment, these questions can help you avoid surprises:

• Do you accept my insurance plan?
• Are you in-network or out-of-network?
• Do you verify benefits before the first visit?
• Do you handle prior authorization, or is that my responsibility?
• Do you bill the medication, monitoring, and office visit separately?
• If you are out of network, do you provide a superbill I can submit for reimbursement?
• What would I owe if insurance denies coverage?

These are not hypothetical concerns. The way clinics bill Spravato — drug cost, administration, observation period, office visit — can vary, and each component may be covered differently by your plan.

Frequently asked questions

Does insurance cover ketamine therapy? Sometimes, but usually only Spravato (esketamine nasal spray) for qualifying diagnoses. IV ketamine for depression is typically self-pay because it is not FDA-approved for psychiatric conditions.

Is Spravato more likely to be covered than IV ketamine? Yes. Spravato has FDA-approved indications for treatment-resistant depression and MDD with acute suicidal ideation. That FDA approval is the main reason insurers are more willing to cover it.

Does Medicare cover ketamine therapy? Medicare may cover Spravato in some circumstances under Part B, since it is a provider-administered drug given in a certified setting with monitoring. IV ketamine for depression is unlikely to be covered. Patients should verify with their specific plan.

Does Medicaid cover ketamine treatment? It varies by state and plan. Some state Medicaid programs publish Spravato prior-authorization criteria, but requirements differ. Check with your specific Medicaid plan.

What insurance companies cover Spravato? Aetna, Cigna, UnitedHealthcare, Premera, and others publish coverage policies for Spravato. But having a published policy does not guarantee every plan under that insurer covers it — always verify with your specific plan.

Does insurance cover IV ketamine infusions for depression? Usually not. Most insurers classify IV ketamine for depression as off-label or investigational. Major hospitals like Massachusetts General Hospital tell patients directly to expect out-of-pocket costs for IV ketamine.

Does insurance cover at-home or oral ketamine? Generally no, when used for psychiatric conditions. The FDA has not approved ketamine for psychiatric disorders, and insurers typically treat non-Spravato formulations as investigational.

What should I do if my claim is denied? Ask for the denial reason in writing, find out whether additional documentation could help, and consider filing an appeal. Medicare has a formal five-level appeal process for drug coverage decisions.

Finding a provider

If you are looking for a ketamine clinic that works with insurance or offers Spravato, our directory lists providers across the country. You can browse by location or clinic type to compare what is available near you.

Related Articles

• How Much Does Ketamine Therapy Cost?
• What Does Ketamine Therapy Feel Like?

Sources

• FDA. Spravato Prescribing Information.
• FDA. Potential Risks Associated with Compounded Ketamine Nasal Spray.
• Aetna. Esketamine (Spravato) — Medical Clinical Policy Bulletin.
• Aetna. Ketamine for the Treatment of Depression and Other Selected Indications.
• Cigna. Spravato Prior Authorization Policy.
• UnitedHealthcare. Ketalar and Spravato — Commercial Medical Benefit Drug Policy.
• Premera Blue Cross. Spravato (Esketamine) Nasal Spray Policy.
• Medicare.gov. Prescription Drug Coverage — Outpatient.
• Medicare.gov. Appeals in a Medicare Drug Plan.
• Massachusetts General Hospital. Ketamine Clinic for Depression.
• Johns Hopkins Medicine. Treatment-Resistant Esketamine Program.
• Spravato REMS. Risk Evaluation and Mitigation Strategy.
• Johnson & Johnson. SPRAVATO withMe Patient Cost Support.